Compare Novo Nordisk A/S (NVO) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Global X Robo Global Robotics & Automation ETF — how do they compare? Novo Nordisk A/S trades at $46.46 (market cap $207.85B), while Global X Robo Global Robotics & Automation ETF trades at $84.26. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Global X Robo Global Robotics & Automation ETF pays none, and Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | ROBO | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $90.34 |
52-Week Low | $35.29 | $62.34 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
ROBO, a US-listed robotics and automation ETF, trades at $84.76, up 1.56% today amid a bullish technical setup with strong moving average support. Key financial ratios are not disclosed for the ETF, but thematic focus on AI-driven robotics gains traction. Recent news highlights sector momentum and strategic rebalancing toward physical AI infrastructure.
Outlook remains positive given bullish technical signals and sector tailwinds, though high RSI suggests near-term overbought risk. Investors gain diversified exposure to robotics growth, but face volatility from cyclical end markets and valuation pressures as AI themes mature.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
